# Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

> **NCT07486960** · PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 140 (estimated)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** Tulisokibart
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07486960
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-20
- **Primary completion:** 2027-08-13
- **Final completion:** 2030-01-11
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07486960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07486960, "Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07486960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*